Literature DB >> 26115613

Pharmacokinetics of adalimumab in Crohn's disease.

David Ternant1, Konstantinos Karmiris, Severine Vermeire, Céline Desvignes, Nicolas Azzopardi, Theodora Bejan-Angoulvant, Gert van Assche, Gilles Paintaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26115613     DOI： 10.1007/s00228-015-1892-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.

Authors:  Zhenhua Xu; Kathleen Seitz; Adedigbo Fasanmade; Joyce Ford; Paul Williamson; Weichun Xu; Hugh M Davis; Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2008-04-09       Impact factor: 3.126

2.  Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Joyce Ford; Danika Hernandez; Jewel Johanns; Chuanpu Hu; Hugh M Davis; Honghui Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

3.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Authors:  Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink
Journal:  JAMA       Date:  2011-04-13       Impact factor: 56.272

4.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

Authors:  Konstantinos Karmiris; Gilles Paintaud; Maja Noman; Charlotte Magdelaine-Beuzelin; Marc Ferrante; Danielle Degenne; Karolien Claes; Tamara Coopman; Nele Van Schuerbeek; Gert Van Assche; Severine Vermeire; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2009-08-05       Impact factor: 22.682

5.  Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.

Authors:  David Ternant; Denis Mulleman; Francine Lauféron; Céline Vignault; Emilie Ducourau; Daniel Wendling; Philippe Goupille; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

6.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Authors:  Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink
Journal:  Ann Rheum Dis       Date:  2007-02-14       Impact factor: 19.103

7.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Authors:  Michael H Weisman; Larry W Moreland; Daniel E Furst; Michael E Weinblatt; Edward C Keystone; Harold E Paulus; Leah S Teoh; Raja B Velagapudi; Peter A Noertersheuser; G Richard Granneman; Steven A Fischkoff; Elliot K Chartash
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

8.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.

Authors:  R L West; Z Zelinkova; G J Wolbink; E J Kuipers; P C F Stokkers; C J van der Woude
Journal:  Aliment Pharmacol Ther       Date:  2008-08-08       Impact factor: 8.171

9.  Infliximab pharmacokinetics in inflammatory bowel disease patients.

Authors:  David Ternant; Alexandre Aubourg; Charlotte Magdelaine-Beuzelin; Danielle Degenne; Hervé Watier; Laurence Picon; Gilles Paintaud
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

10.  Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Authors:  David Ternant; Emilie Ducourau; Piéra Fuzibet; Céline Vignault; Hervé Watier; Thierry Lequerré; Xavier Le Loët; Olivier Vittecoq; Philippe Goupille; Denis Mulleman; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335
View more
  6 in total

1.  Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  J Crohns Colitis       Date:  2016-02-13       Impact factor: 9.071

Review 2.  Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.

Authors:  Antoine Petitcollin; Amina Bensalem; Marie-Clémence Verdier; Camille Tron; Florian Lemaitre; Gilles Paintaud; Eric Bellissant; David Ternant
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

Review 3.  Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Authors:  David Ternant; Nicolas Azzopardi; William Raoul; Theodora Bejan-Angoulvant; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 4.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04

5.  Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients.

Authors:  Sonia Facchin; Andrea Buda; Romilda Cardin; Nada Agbariah; Fabiana Zingone; Manuela De Bona; Debora Zaetta; Lorenzo Bertani; Matteo Ghisa; Brigida Barberio; Edoardo Vincenzo Savarino
Journal:  Therap Adv Gastroenterol       Date:  2021-03-21       Impact factor: 4.409

6.  Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.

Authors:  Beatriz Orts; Ana Gutierrez; Lucía Madero; Laura Sempere; Ruben Frances; Pedro Zapater
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.